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Aim: Targeted temperature management (TTM) in post-resuscitation care has changed dramatically over the last
two decades. However, uptake across Australian and New Zealand (NZ) intensive care units (ICUs) is unclear. We
aimed to describe post-resuscitation care in our region, with a focus on TTM, and to gain insights into clinician’s
opinions about the level of evidence supporting TTM.
Methods: In December 2017, we sent an online survey to 163 ICU medical directors in Australia (n ¼ 141) and NZ
(n ¼ 22).
Results: Sixty-one ICU medical directors responded (50 from Australia and 11 from NZ). Two respondents were
excluded from analysis as their Private ICUs did not admit post-arrest patients. The majority of remaining re-
spondents stated their ICU followed a post-resuscitation care clinical guideline (n ¼ 41/59, 70%). TTM was used
in 57 (of 59, 97%) ICUs, of these only 64% had a specific TTM clinical guideline/policy and there was variation in
the types of patients treated, temperatures targeted (range ¼ 33–37.5 C), methods for cooling and duration of
cooling (range ¼ 12–72 h). The majority of respondents stated that their ICU (n ¼ 45/57, 88%) changed TTM
practice following the TTM trial: with 28% targeting temperatures >36 C, and 23 (of 46, 50%) respondents
expressed concerns with current level of evidence for TTM. Only 38% of post-resuscitation guidelines included
prognostication procedures, few ICUs reported the use of electrophysiological tests.
Conclusions: In Australian and New Zealand ICUs there is widespread variation in post-resuscitation care,
including TTM practice and prognostication. There also seems to be concerns with current TTM evidence and
recommendations.Introduction
Targeted temperature management (TTM) is recommended in inter-
national guidelines to reduce the neurological injury that occurs after
cardiac arrest.1 The active cooling of patients post-cardiac arrest was first
recommended by the International Liaison Committee on Resuscitation
(ILCOR) in 20032, following the publication of two seminal randomised
control trials.3,4 At that time, international guidelines recommended
cooling patients to a therapeutic hypothermia (TH) range of 32–34 C.5,6
However, subsequent international surveys suggested institutional up-
take of TH for cardiac arrest was low (<50%),7–9 with a lack of policy,
information, resources, equipment and expertise identified asl 3, 553 St Kilda Rd, Melbourne,
ay).
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The recommended targeted temperature for this treatment was
expanded, from a range of 32–34 C to 32–36 C,13,14 following results
from the Targeted Temperature Management Trial (TTM trial) in 201315
which found no difference in patient outcomes within this temperature
range. International surveys conducted immediately following the TTM
trial publication suggest more ICUs have adopted cooling post-cardiac
arrest (91%–94%), but that implementation of TTM varied greatly.16,17
Understanding why this variation in practice is occurring is vital to
informing future research and guideline recommendations.
Current post-resuscitation practice, including TTM practice, in our
region of Australia and New Zealand is unknown. Although, recentVictoria, 3004, Australia.
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Table 2
Post-resuscitation practice in participating ICUs.
Characteristic Participating n ¼ 61 (%)
Follows a Post-Resuscitation guideline 41/59 (69)
Pre-defined targets for MAP 27/41 (66)
Pre-defined targets for pCO2 25/41 (61)
Pre-defined targets for pO2 26/41 (63)
Pre-defined targets for glucose 26/41 (63)
TTM usage (n ¼ 51)
TTM clinical guideline 33/51 (64)
TTM pre-ICU 9/51 (18)
Duration
12 h 2 (4)
24 h 35 (68)
28 h 3 (6)
36 h 3 (6)
48 h 4 (8)
60 h 1 (2)
72 h 1 (2)
unsure 2 (4)
Cooling devices
Inductiona (n ¼ 51)
Ice packs 29 (57)
Cold fluid 27 (53)
Cooling blankets 36 (71)
Endovascular 5 (10)
Other (cooling device, mattress, paracetamol) 4 (8)
Maintenancea (n ¼ 51)
Ice packs 20 (39)
Cold fluid 13 (25)
Cooling blankets 38 (75)
Endovascular 6 (12)
Other (cooling device, mattress) 3 (6)
a More than one response allowed.
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occurred following the TTM trial,18,19 and current practice may not be
following the Australian and New Zealand Committee on Resuscitation
(ANZCOR) post-resuscitation guidelines.20 In this study, we surveyed
ICU Medical Directors in Australia and New Zealand with the aim of
describing elements of post-resuscitation care, including any changes in
practice following publication of the TTM Trial and to examine their
opinions on the current level of evidence for TTM.
Method
In December 2017, we conducted an online survey of medical di-
rectors for all ICUs registered in the Australian and New Zealand Inten-
sive Care Society (ANZICs). Completion of the survey was voluntary and
the study was approved by the Monash University Human Ethics
Committee.
ICU Medical Directors were emailed an invitation to participate, with
the exclusion of specialty hospitals, and the survey was completed on
Survey Monkey. A second email was sent if a response was not received
within four weeks. The questionnaire consisted of multiple choice and
open-ended responses. Questions were derived from the findings of
previous work,7–9 and on advice from experts in resuscitation from the
Australian Resuscitation Outcomes Consortium (Aus-ROC) and the
ANZICS Research Committee. Prior to release, the questionnaire was
evaluated for face validity among Aus-ROC investigators and piloted first
at hospitals associated with these investigators. We also validated re-
sponses against the clinical guidelines if these were provided by the ICU
Medical Directors.
Data analysis was descriptive, and comparisons were made using the
Fisher’s exact test. Content analysis was performed by one investigator
(JB) on the open-ended response regarding the current level of evidence
for TTM. Statistical analysis was performed in Stata with a p-value<0.05
considered statistically significant.
Results
Sixty-one ICU medical directors responded to the survey (response
rate ¼ 37%) – with representation from both countries (50 in Australia
and 11 in NZ), all categories of ICUs and all states and regions (Table 1).
The majority of respondents (n¼ 59, 97%) were from ICUs admitting
cardiac arrest patients. Of these, 41 respondents (69%) stated their ICUTable 1
Characteristics of participating and non-participating ICUs.
Characteristic Overall
N ¼ 163
Participating
N ¼ 61
Non-participating
N ¼ 102
Tertiary level 38 (23%) 17 (28%) 21 (21%)
Private 56 (34%) 16 (26%) 40 (39%)
Metropolitan 30 (18%) 7 (12%) 23 (23%)
Rural/regional 34 (21%) 19 (31%) 15 (15%)
Paediatric ICU 5 (3%) 2 (3%) 3 (3%)
Country
Australia 141 (87%) 50 (82%) 91 (89%)
New Zealand 22 (13%) 11 (18%) 11 (11%)
Australian State/Territory
Victoria 36 (25%) 10 (20%) 26 (28%)
New South Wales 51 (36%) 16 (32%) 35 (38%)
Queensland 26 (18%) 12 (24%) 14 (15%)
Western Australia 12 (8%) 5 (10%) 7 (8%)
South Australia 11 (8%) 3 (6%) 8 (9%)
Tasmania 3 (2%) 1 (2%) 2 (2%)
ACT 2 (1%) 2 (4%) 0 (0%)
Northern Territory 2 (1%) 1 (2%) 1 (1%)
ICU beds
3-9 23 (38%)
10-19 22 (36%)
20-30 9 (15%)
>30 7 (11%)
2used a post-resuscitation clinical guideline (Table 2). The majority of
these respondents reported using clinical guidelines that specified hae-
modynamic parameters, but few guidelines (19/50, 38%) included
prognostication procedures. Few respondents reported (the use of so-
matosensory evoked potential (SSEP, 9/50) or electroencephalography
(EEG, 16/50) to inform prognostication.
TTM was used in 97% (n ¼ 57/59) of ICUs as a component of post-
resuscitation care. Two respondents reported TTM was not adminis-
tered in their ICUs, and stated this was because of a lack of expertise and
resources (rural ICU respondent), and because of the lack of scientific
evidence (tertiary metropolitan ICU respondent).
Of the 57 ICUs providing TTM, 51 (89%) provided details of TTM
practice. Following the TTM trial publication, the majority of ICUs (n ¼
45/51, 88%) changed their target temperature practice (Fig. 1). This
change was not associated with hospital type (88% teaching vs 88% non-
teaching) or location (89% metropolitan vs. 88% rural, p ¼ 0.62), and
was reported by 100% of New Zealand and 85% of Australian re-
spondents. Only 19% (n ¼ 10) reported restricting TTM to a subset of
patients, the majority of these ICUs (n ¼ 9) restricted TTM to patients
with a shockable rhythm, with one ICU restricting based on witnessed
status.
The majority of respondents reported changing to the TTM RCT
protocol. However, there was a wide range of target temperatures re-
ported, with 28% of ICUs targeting temperatures greater than 36 C (92%
of this subset were teaching hospitals and 100% were in Australia) and
6% were targeting normothermia (Fig. 2). The duration of TTM varied
between 12 and 72 h, with the majority (69%) reporting a 24-h treatment
window. The ICUs used various cooling methods, with the most common
method being cooling blankets (71%).
Almost half (n ¼ 23/46) of the respondents expressed concerns with
the current level of evidence for TTM. Specific themes of their concern
were: whether the evidence was sufficient; design flaws in the existing
randomised controlled trials (RCTs); and, applicability of RCTs to prac-
tice (Table 3).
Fig. 1. Changes to Target Temperature Management following the TTM RCT 2013 publication.
Fig. 2. Target Temperatures reported by ICU Medical Directors.
Table 3
Themes, and supporting quotes, identified in response to the question “Do you
have any concerns with the current level of evidence for TTM post cardiac
arrest?”.
TTM Supporting quotes
Insufficient
evidence
“The TTM trial needs to be replicated. There are issues with the
time to significantly different temps and also the bias of clinicians
observing neurology in patients with hypothermia induced delayed
excretion of sedative agents.”
“Not much evidence- really just lack of harm”.
“Too few studies”.
Design flaws in
trials
“Temperature management in ICU is too late.”
“All studies have major weakness/design flaws that limit clinical
utility.”
“Non-inferiority trial would be better with a RCT designed to see if
TTM is better than TH management”
“Suggests hypothermia useful. Never tested whether avoidance of
hyperthermia is as efficacious.”
“There is no conclusive evidence about its efficacy.”
“The "evidence’ from TTM Nielsen study did not test the upper
limit of temperature that can be tolerated without any harm.”.
Applicability to
practice
“Still not sure about the < 36. Currently doing an audit to see how
much normothermia occurs. When targeted 32–33, no
normothermia during cooling phase.”
“Seems to change very frequently and is not uniformly applied.”
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3Discussion
Our online survey of Australian and New Zealand ICU medical di-
rectors indicates a wide variation in the delivery of post-resuscitation
care. There has been a large shift in TTM practice, with the majority of
respondents stating their ICU had changed practice following the TTM
trial. However, our data also shows that not all ICUs are following the
current ANZCOR guideline,20 with 28% of ICUs targeting temperatures
over 36 C.
Our data provides further evidence supporting the recent report from
the Australian and New Zealand Intensive Care Society (ANZICS) Adult
Patient Database. Salter et al.19 found a significant shift in the lowest and
highest recorded temperatures in the first 24 h of ICU in cardiac arrest
patients in the period following publication of the TTM trial. Similar
changes have also been reported in ICU admissions in the UK.21 Alarm-
ingly, in both these studies, OHCA mortality was trending down the
decade preceding the publication of the TTM trial, but increased for the
first time in the years following. This may be explained by a combination
of difficulties in implementing a 36 C protocol,18 and potentially by a
misinterpretation of the TTM trial as a negative study and an abandon-
ment of this treatment all together. It is also possible that this change in
mortality reflects a wider spread change in attitude and practice to
post-resuscitation care, including earlier prognostication. However, most
J.E. Bray et al. Resuscitation Plus 1-2 (2020) 100002before-and-after studies have not reported changes in other aspects of
care (e.g. coronary angiogram),18,22,23 and the large registry studies
suggest no change in time in ICU either overall or in non-survivors19,21
There is a growing body of evidence showing significant decreases in
TTM administration following the TTM trial,24–26 and our data suggest
over a quarter of ICUs are now targeting normothermic temperatures.
Despite recommendations from leading bodies, such as ILCOR27 and
Resuscitation Councils,20 and the widespread adoption of TTM, there
appears to be divide among the medical community concerning the
current level of evidence for TTM28 which may explain why some ICUs
are now practicing outside of guideline recommendations. Key themes
expressed by half of our respondents surround insufficient evidence, ef-
ficacy of treatment and applicability to clinical practice. Such concerns
were also seen internationally from clinicians following publication of
the TTM trial.29,30 Some respondents in our study described the
“normothermia” seen in the 36 C arm of the TTM trial. The TTM trial
temperature curves showmean temperatures of approximately 36 C, but
the 95% confidence intervals extend into the “normothermic” range.
However it is important to note that no patients in the TTM trial expe-
rienced fever in the first 24-h, but subsequent implementation of the 36
C protocol into clinical practise has seen significant increases in patients
with fever in some studies.18,19 This was also seen in the recent HYPE-
RION trial in non-shockable arrests. Although, not specifically reported,
the confidence intervals of the temperature curves in the normothermic
group in HYPERION were within the febrile range.31 The TTM-2 trial,32
which is has recently completed recruitment, will compare therapeutic
hypothermia at 33 C with normothermia and early treatment of fever
(37.8 C), may allay some the concerns with the current level of
evidence.
Our study also demonstrated other variations in TTM treatment and
post-resuscitation care–including the duration of TTM, use of cooling
devices, prognostication and use of specific a post-resuscitation care
clinical guideline. Similar variations have been reported in other inter-
national ICU surveys.17,33 The variation seen in duration and cooling
methods most likely reflects those used in clinical trials. For example, the
duration of TTM varies in trials between 123 and 7234 h, as there not
currently any clear evidence of the optimal TTM duration in adults27 or
children.35 There is also no clear consensus on cooling devices, although
a recent review suggests some methods may be superior to others.36
Although we only asked limited questions about prognostication, we
found only one-third included prognostication in their clinical guideline
and few used SSEP and EEG. These findings require further investigation
to uncover what other tests are currently in widespread use. There is also
the need for large audit of care in our region to examine whether the
variation in post-resuscitation care, particularly care that does not adhere
to guideline recommendations, impacts on patient outcomes. This has
been reported elsewhere,37 and may be needed in our region to change
future practice. Alternately, trials investigating the standardisation of
post-resuscitation care across ICUs,38 or transport to cardiac arrest cen-
tres,39 may be worth investigating to ensure patients receive optimal
care.
Our study has a number of limitations. The survey was conducted in
December 2017, and may not reflect current practice and may only
reflect practice in Australian and New Zealand. The response rate was
less than ideal, and there are some differences in the characteristics of the
responding ICUs (Table 1). Also not all participants answered all ques-
tions on the survey, and our survey may be subject to responder bias (i.e.
those who changed practice may have been more likely to respond).
Responses were checked against post-resuscitation clinical guidelines/
protocols when these were provided.
Despite these limitations, our study provides important data on post-
arrest care in Australia and New Zealand ICUs. Our data indicates areas
requiring further research, such as prognostication, as well as a shift and
wide variation in TTM practice. Our study also identifies current con-
cerns of the ICU medical specialists, which will need to be overcome to
achieve a standardisation of TTM post-resuscitation care.4Funding
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